Workflow
注射用甘草酸二铵
icon
Search documents
重庆华森制药两药品获再注册批准,短期业绩影响不大
Xin Lang Cai Jing· 2025-09-24 08:14
近日,重庆华森制药股份有限公司收到重庆市药监局核准签发的1个化学原料药(甘草酸二铵)的《化 学原料药再注册批准通知书》和1个药品(注射用阿魏酸钠)的《药品再注册批准通知书》。甘草酸二 铵用于生产注射用甘草酸二铵,注射用阿魏酸钠用于缺血性心脑血管病的辅助治疗。此次再注册批准将 确保相关药品正常生产和销售,公司会严格把控产品质量。不过短期内对公司经营业绩无重大影响,提 醒投资者谨慎决策,注意风险。 ...
重庆华森制药股份有限公司关于公司收到药品再注册批准通知书的公告
登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 重庆华森制药股份有限公司(以下简称"公司")于近日收到重庆市药品监督管理局(以下简称"市药监 局")核准签发的关于公司2个药品的《药品再注册批准通知书》。现将相关情况公告如下: 英文名/拉丁名:Diammonium Glycyrrhizinate for Injection 受理号:CYHZ2540457渝 通知书编号:2025R076063 剂型:注射剂 规格:150mg 注册分类:化学药品:无 一、《药品再注册批准通知书》主要信息 (一)小儿咽扁颗粒 (二)注射用甘草酸二铵 药品通用名称:注射用甘草酸二铵 2.注射用甘草酸二铵:本品用于伴有丙氨酸氨基转移酶(ALT)升高的急、慢性病毒性肝炎。 三、药品其他相关信息 近年来,儿科中成药市场再创新高,根据米内网数据,2024年中国三大终端六大市场儿科中成药销售额 达183亿元,创下历史新高。其中,儿科感冒用药占比37.23%、儿科止咳祛痰用药占比34.40%,二者合 计市场份额超70%。小儿咽扁颗粒为北京首都儿科研 ...
华森制药:小儿咽扁颗粒与注射用甘草酸二铵获再注册批件
Cai Jing Wang· 2025-08-18 18:02
Core Viewpoint - Huason Pharmaceutical has received drug re-registration approval for two products, indicating a positive development in its product portfolio and market presence [1][2]. Group 1: Product Details - The company received approval for "Pediatric Throat and Tonsil Granules," which is used for treating symptoms like sore throat and cough in children [1]. - The second product, "Injectable Glycyrrhizin Ammonium," is indicated for acute and chronic viral hepatitis with elevated ALT levels, showcasing its comprehensive liver protection effects [2]. Group 2: Market Insights - The pediatric traditional Chinese medicine market in China is projected to reach 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [1]. - The approval of these products aligns with the growing demand for pediatric medications, particularly in the context of rising sales in the sector [1]. Group 3: Regulatory and Quality Assurance - The approval ensures the normal production and sales of the mentioned drugs, with the company committing to strict quality control measures [2]. - The injectable glycyrrhizin ammonium has been included in several national and international liver disease management guidelines, reinforcing its credibility and market position [2].
华森制药:关于公司收到药品再注册批准通知书的公告
Zheng Quan Ri Bao· 2025-08-18 14:12
Group 1 - The company, Huason Pharmaceutical, announced the receipt of two drug re-registration approval notices from the Chongqing Drug Administration [2] - The approved drugs include Pediatric Pharyngeal Tonsil Granules and Injection Glycyrrhizic Acid Disodium [2]